LATEST ALERTS
Medical use of psilocibyn in Canada could grow, but consumer sale unlikely
13th August 2021 - News analysis |
A court case could force the Canadian government to process requests to use psilocybin for psychotherapeutic treatment more quickly
Health and science
Testing the testers: UK and US CBD testing labs go under the microscope
13th August 2021 - News analysis |
A recent ring trial assessment of the lab performances and methods for measuring CBD in commercial products has given some good news to the industry
What lies behind the CBD industry’s continued interest in the field of nicotine replacement?
11th August 2021 - Blogs , News analysis |
A new study has shown some limited effectiveness for the use of CBD in combatting nicotine withdrawal symptoms
Test-tube cannabinoids: scientists seek alternatives to agricultural production
11th August 2021 - News analysis |
New methods for laboratory production of cannabinoids show some promise – but it’s still not clear whether they will yield enough to be commercially viable
Study raises early hopes for the use of CBD in treating nicotine withdrawal
5th August 2021 - News analysis |
Researchers at the University of San Diego in California have published a paper showing early evidence that CBD may help ease the symptoms of nicotine withdrawal
Public health insurance is driving growth of the German medical cannabis market
3rd August 2021 - News analysis |
Public health insurance reimbursements and no defined list of indications for medical cannabis have helped the German medical cannabis market start to realise its massive potential
Watchdog study finds high levels of inaccuracy in delta-8 THC labels
28th July 2021 - News analysis |
Research from a CBD watchdog firm has found considerable inconsistencies between the levels of delta-8 THC stated on product labels and what was revealed by laboratory tests
Researchers find even synthetic CBD can degrade and produce THC if badly stored
26th July 2021 - News analysis |
Both synthetic and plant-derived CBD degrade when stored incorrectly, producing THC, according to a new study
Company behind the UK’s first medical cannabis vape aims to lead a revolution
22nd July 2021 - News analysis |
London-listed Kanabo has launched the first medical cannabis vaping product in the UK in a move the company’s founder hopes will ultimately revolutionise the way medicines are administered
Javid appointment as UK health minister raises slight hope for medical cannabis
19th July 2021 - News analysis |
Medical cannabis advocates are keen to see if Sajid Javid’s appointment as UK health secretary means he will continue his work from 2018, when he helped change the law on medicinal cannabis prescriptions
Clinical trials to explore potential of psychedelics are on the rise in Europe
16th July 2021 - News analysis |
A range of European firms are looking to further advance research into psychedelic compounds after securing funding and backing
A long process – Europe’s still asking questions about novel food submission
14th July 2021 - News analysis |
A year and eight months after Cibdol submitted its novel food application for EU authorisation of synthetically produced CBD, the Swiss company is still fielding questions from the European Food Safety Authority (ESFA)
More minor cannabinoids – could THCP and CBDP offer an interesting side dish?
1st July 2021 - News analysis |
What are the potential implications for the cannabinoids market of two recently discovered compounds with chemical structures similar to those of CBD and THC – and what are they and their potential effects anyway?
Freeing the ‘green pig’ – moves afoot to press France to legalise cannabis
29th June 2021 - News analysis |
France is lagging behind its neighbours on medical cannabis – the potential “green pig” of French agriculture – according to an author of a report which called for it to be legalised on health and finance grounds
Podcast: Hemp growing challenges in the UK
29th June 2021 - Podcasts |
CBD-Intel podcast editor Jon Bruford discusses the situation of medical cannabis and the challenges of hemp-growing in the UK with Dr Callie Seaman, research director at Aqualabs Ltd
Combining other topical ingredients with cannabinoids goes more than skin-deep
16th June 2021 - News analysis |
Trends such as sustainability and organic plant-based ingredients are helping to drive the market for hemp and cannabinoid topical products even higher, with combination products all the rage
Initial results from Project Twenty21 reveal promise – and a few caveats
26th May 2021 - News analysis |
CBD-Intel assesses how Project Twenty21 is faring as it seeks to construct a registry of medical cannabis users in the UK and Europe, providing real world data on potential efficacy
Cannabinoids, cannabis and pain: a promising area for further research
13th May 2021 - News analysis |
Pain is a familiar part of everybody’s life, yet it remains a remarkably hard subject to study. It therefore is unsurprising that studies have come to differing conclusions on the use of cannabis and cannabinoids for pain relief
Minor cannabinoids: what are they, and how could they be of benefit?
28th April 2021 - News analysis , Resources |
CBD-Intel offers a review of the science behind some of cannabis’s lesser-known compounds – the so-called “minor cannabinoids” – with an emphasis on their potential applications
Reasons for CBD use are increasing and diversifying in the UK
27th April 2021 - News analysis , Resources |
In comparison with our 2019 consumer survey results, the reasons given for using CBD have changed and diversified
CBD and Covid-19 – lab experiments show promise, but don’t hold your breath
21st April 2021 - News analysis |
Early research into the possibility of CBD having a role to play in the fight against coronavirus infections has shown some initial promise. Any practical application remains a long way off, however
Cann Group teams up with Emyria to develop pharmacy grade CBD capsules
21st April 2021 - News analysis |
Australian medicinal cannabis firm Cann has moved quickly to maximise the benefits of its CBD Gelpell capsule technology by entering into a collaboration deal with healthcare technology firm Emyria
The next big thing – or are investors in psychedelics playing the long game?
19th April 2021 - News analysis |
While legal cannabis is still a relatively new industry, investors are already looking for the next sector to boom – and many think that will be psychedelics
Tilray expands its influence Down Under, moving on New Zealand medical market
15th April 2021 - News analysis |
Canadian cannabis firm Tilray is moving in on New Zealand’s market for medical cannabis and has received the necessary approvals to launch Tilray medical cannabis products across the country
How cannabis derivatives could help to preserve the miracle of modern medicine
13th April 2021 - News analysis |
Could cannabinoids, including CBD, provide a partial solution to the growing danger of diseases becoming resistant to existing antibiotics?
Could cannabinoids help in the fight against drug-resistant bacteria?
12th April 2021 - News analysis |
Scientific findings on the antimicrobial properties of cannabis – and in particular cannabinoids – have raised the question of whether they might play a role in combatting antibiotic-resistant bacteria such as MRSA
FTC-targeted company remains defiant, sees administrative fine as a victory
26th March 2021 - News analysis |
The CEO of one company targeted by the US Federal Trade Commission (FTC) in the first ever group of fines handed down by the government agency to CBD companies considers the event to be a David and Goliath victory of sorts
ValidCare reports to US FDA that trials find no evidence of CBD liver toxicity
23rd March 2021 - News analysis |
No evidence of liver toxicity from CBD has been found in the ValidCare study, the results of which have been given to the US Food and Drug Administration (FDA) for review
PG/phytol research should come with a health warning – lab rats are not humans
19th March 2021 - News analysis |
Any conclusion drawn from studies on rodents must be treated with caution if we want to know about effects on humans
Pregnant mice study touches on FDA questions, but more research is needed
12th March 2021 - News analysis |
The US Food and Drug Administration (FDA) has called for an exploration of the effects of CBD on certain vulnerable populations such as children and pregnant women as part of its consumer update
Jazz Pharmaceuticals buys Epidiolex manufacturer GW Pharma for $7.2bn
3rd February 2021 - News analysis |
GW Pharmaceuticals, the British manufacturer of the CBD-based epilepsy drug Epidiolex, has been acquired by Jazz Pharmaceuticals in a cash and shares deal worth over $7bn
Financial investments suggest a mood of optimism around CBD and cannabis
26th January 2021 - News analysis |
Renewed interest in financing of CBD and cannabis businesses could signal that investors are starting to be positive again about the future after companies seemingly weathered the worst of the storm in 2020
Dutch health ministry provides relief for UK patients forgotten in Brexit deal
25th January 2021 - News analysis |
Dutch officials have granted a six-month reprieve to find a solution to an omission in the Brexit negotiations that threatens to deprive British epilepsy patients of access to cannabis-based medicines
COVID-19: emergency regulations and affected legislative procedures
14th January 2021 - Regulatory alerts roundup |
Find all of CBD-Intel’s coronavirus-related regulatory alerts here, updated as they appear
It could have been so much worse: 2020 was CBD’s year in the waiting-room
1st January 2021 - News analysis |
For many 2020 will always carry an asterisk. The CBD industry was – overall – more fortunate than many other sectors
Delay and dispute over deal to get CBD into Brazil’s public health system
30th December 2020 - News analysis |
Efforts to supply the first CBD product to Brazil’s public healthcare system will have to wait a while longer – and there is some dispute between the institute preparing to produce it and the sponsors of a Congress bill
I’m a celebrity – get me into quality cannabis, hemp and CBD brands…
23rd December 2020 - News analysis |
Increasing numbers of celebrities are endorsing CBD products, with names as big as will.i.am, Jay-Z, Beyoncé and Gwyneth Paltrow among those investing or launching their own brands
Avazo has its collar felt by the FDA/FTC over ‘unsubstantiated COVID-19 claims’
14th December 2020 - News analysis |
Another company has been warned by the US Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) to stop claiming CBD can cure or mitigate the symptoms of COVID-19
How far-reaching an impact could the CJEU Kanavape decision have?
11th December 2020 - Blogs |
The Court of Justice of the European Union’s (CJEU) decision in the Kanavape case will have a tremendous impact on the CBD industry in the European Union (EU). However, the breadth of its impact is not yet fully realised. A number of things must happen beforehand and it may come down to further court rulings before a baseline level of requirements and » Continue Reading.
Trials and research into the healing potential of cannabinoids continue
11th December 2020 - News analysis |
Pharmaceutical firms continue to invest in research into the healing potential of cannabinoids, launching clinical trials to investigate their ability to treat a range of conditions
Watchdog warns phony ‘research’ claims risk undermining consumer confidence
8th December 2020 - News analysis |
While solid research explaining the science behind CBD remains lacking as the market continues to grow, some bad actors in the industry are making false scientific claims for their products
What does the European Commissions (EC)’s change in opinion on CBD as a narcotic mean?
4th December 2020 - Blogs |
The announcement is a full reversal from the EC on a position that many found surprising in the first place. It marks a stellar period for the regulation of CBD and other cannabinoids with major decisions in their favour at the Court of Justice of the European Union, United Nations and now the EC. The resumption of novel food assessment » Continue Reading.
Canadian public and industry back plan to free CBD from cannabis regulation
1st December 2020 - News analysis |
The results of Canada’s public consultation on health products containing cannabis have been released, showing strong support for allowing the sale of CBD outside the current cannabis restrictions
The British isle heading for its own rules on cannabinoid extraction for export
1st December 2020 - News analysis |
The Isle of Man looks likely to become the second jurisdiction operating under UK regulations to allow the use of hemp flowers in extraction
What impact will Black Friday sales have on the CBD sector?
27th November 2020 - Blogs |
Overall it seems the industry – particularly in Europe – is not expecting much from Black Friday sales. European companies appear to consider CBD products more as health products that are requirement purchases throughout the year as opposed to lifestyle products that might be purchased as a one off during a special sales event. The situation may be slightly different in the US where Black Friday – » Continue Reading.
How important is the CJEU decision on the Kanavape case?
20th November 2020 - Blogs |
How important is the CJEU decision on the Kanavape case? The judgement in favour of CBD from the Courts of Justice of the European Union (CJEU) will almost certainly have significant long-term consequences for the CBD industry in Europe. It will likely influence the European Commission (EC)’s further assessment of the question of whether CBD is a narcotic. The preliminary opinion » Continue Reading.
The good, the bad and the troublesome – could CBD and nicotine make a match?
17th November 2020 - News analysis |
CBD, generally seen as a health or wellness product, and “bad guy” nicotine are almost opposites in terms of public perception – but could putting the two together make commercial sense?
Where are we most likely to see changes to medical and recreational cannabis regimes?
13th November 2020 - Blogs |
Mexico is overall the number one country to watch, rated highly likely to change regulations on both medical and recreational cannabis in the near future.
US FDA issues warning letter over COVID-19 health claims
30th October 2020 - News analysis |
The US Food and Drink Administration (FDA) has issued a warning letter to the CBD company For Our Vets over COVID-19 health claims
Do companies need toxicological study data included in UK Food Standards Agency (FSA) novel food applications for them to be validated?
9th October 2020 - Blogs |
There are still quite a few unanswered questions regarding the novel food application process under the FSA. Fortunately the requirement of having toxicological data
